The CEOs of both Bristol-Myers Squibb (BMY 0.40%) and Teva Pharmaceutical Industries (TEVA 3.16%) have indicated that they're looking to make deals at the moment. In this video, Motley Fool health-care analyst David Williamson looks at both companies and how successful some of their recent mergers and acquisitions were. He also examines several possible takeover candidates and discusses just how likely each might be for an acquisition by BMY or TEVA. Finally, David tells investors which of the two he sees as stronger at the moment, and how this pricey bull market may affect the companies' decisions.
2014 Trend Alert: Health-Care M&A
By Dave Williamson – Jan 18, 2014 at 5:26PM
Price as of March 21, 2023, 4:00 p.m. ET
Are Bristol-Myers Squibb and Teva on the hunt for some M&A opportunities?
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Our Most Popular Articles
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.